Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects

It has been reported that the artificial sweetener, sucralose, stimulates glucose absorption in rodents by enhancing apical availability of the transporter GLUT2. We evaluated whether exposure of the proximal small intestine to sucralose affects glucose absorption and/or the glycaemic response to an...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of nutrition Vol. 104; no. 6; pp. 803 - 806
Main Authors Ma, Jing, Chang, Jessica, Checklin, Helen L., Young, Richard L., Jones, Karen L., Horowitz, Michael, Rayner, Christopher K.
Format Journal Article
LanguageEnglish
Published Cambridge, UK Cambridge University Press 28.09.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It has been reported that the artificial sweetener, sucralose, stimulates glucose absorption in rodents by enhancing apical availability of the transporter GLUT2. We evaluated whether exposure of the proximal small intestine to sucralose affects glucose absorption and/or the glycaemic response to an intraduodenal (ID) glucose infusion in healthy human subjects. Ten healthy subjects were studied on two separate occasions in a single-blind, randomised order. Each subject received an ID infusion of sucralose (4 mm in 0·9 % saline) or control (0·9 % saline) at 4 ml/min for 150 min (T = − 30 to 120 min). After 30 min (T = 0), glucose (25 %) and its non-metabolised analogue, 3-O-methylglucose (3-OMG; 2·5 %), were co-infused intraduodenally (T = 0–120 min; 4·2 kJ/min (1 kcal/min)). Blood was sampled at frequent intervals. Blood glucose, plasma glucagon-like peptide-1 (GLP-1) and serum 3-OMG concentrations increased during ID glucose/3-OMG infusion (P < 0·005 for each). However, there were no differences in blood glucose, plasma GLP-1 or serum 3-OMG concentrations between sucralose and control infusions. In conclusion, sucralose does not appear to modify the rate of glucose absorption or the glycaemic or incretin response to ID glucose infusion when given acutely in healthy human subjects.
Bibliography:http://dx.doi.org/10.1017/S0007114510001327
istex:F1B1078FE18F25134381A2B22F58D2E1B006DDCE
ark:/67375/6GQ-GNPNSF55-8
ArticleID:00132
Abbreviations: 3-OMG, 3-O-methylglucose; GLP-1, glucagon-like peptide-1; ID, intraduodenal; SGLT1, Na-dependent GLUT 1
PII:S0007114510001327
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0007-1145
1475-2662
1475-2662
DOI:10.1017/S0007114510001327